A Phase III, open-label study to evaluate the effect of ocrelizumab on immune responses in patients with relapsing MS

Authors
Category Primary study
ConferenceEuropean Journal of Neurology
Year 2016
This article has no abstract
Epistemonikos ID: b9b40cdbe5af1755d1c72f94ff3f882df9ed2312
First added on: Apr 30, 2026